info@seagull-health.com
SeagullHealth
语言:
search
new
Can pregnant and lactating women use Binimetinib?
501
Article source: Seagull Pharmacy
Jun 19, 2025

Binimetinib, also known as Mektovi, is a drug used to treat certain types of diseases, particularly melanotic lesions associated with specific gene mutations. It belongs to a class of drugs called MEK inhibitors, which stop the growth and spread of diseased cells by blocking the activity of MEK enzymes. For pregnant and lactating women, the use of Binimetinib requires extreme caution.

Can pregnant and lactating women use Binimetinib?

1. Precautions for pregnant women using Binimetinib

Binimetinib should be avoided during pregnancy. According to animal studies and its mechanism of action, this drug may cause harm to the fetus when given to pregnant women. In animal reproduction studies, Binimetinib was shown to have embryotoxic and abortifacient effects when given to rabbits during organogenesis at doses greater than or equal to approximately 5 times that resulted in exposure to about 5 times that of human exposure.

There are currently no available data on the use of this drug during pregnancy, but there may be potential harm to the fetus, and it is recommended that women of childbearing age use effective contraception during treatment with this drug and for at least 30 days after the last dose.

2. Warning for lactating women to use Binimetinib

Binimetinib should also be avoided during breastfeeding. There is currently no information on the use of the drug during breastfeeding. Since Binimetinib is highly bound to plasma proteins and has a half-life of 3.5 hours, the amount in milk may be low. However, the instructions advise women not to breastfeed during treatment with this medicine and for at least 3 days after the last dose. For patients taking it in combination with encofenib, the instructions recommend stopping breastfeeding during treatment and for at least 2 weeks after treatment.

It is important for patients to understand the potential risks of the medication in detail and follow the doctor's advice before taking the medication. Doctors should also weigh the pros and cons according to the specific situation of the patient and formulate an appropriate treatment plan.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Binimetinib(Mektovi)
Binimetinib(Mektovi)
Adults with advanced or metastatic melanoma with BRAF V600E or V600K mutation.
WeChat Scan
Free Inquiry
Recommended Articles
Precautions for Binimetinib use
Binimetinib is a targeted therapy drug that is primarily used to treat certain types of diseases, especially those associated with BRAF gene mutations.Basic information about BinimetinibBinimetinib is...
Precautions for the use of Binimetinib(Mektovi)
Binimetinib is a targeted drug used to treat specific types of lesions. This article will introduce the precautions for the use of Binimetinib to help patients better understand how to use the drug sa...
Are the adverse effects of Binimetinib(Mektovi) serious?
The severity of adverse reactions to Binimetinib(Mektovi) varies from individual to individual, but in general, most adverse reactions are manageable and not too severe, but some may be serious and re...
Side effects of Binimetinib
Binimetinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 activity, and has shown good efficacy in the treatment of BRAF mutation-positive unre...
Indications for Elacestrant
Elacestrant is a novel estrogen receptor antagonist that is primarily used to treat specific types of breast cancer. It inhibits the growth of tumor cells by targeting the ERα receptor and is suitable...
Elacestrant is used for the treatment of advanced or metastatic breast lesions
Elacestrant, also known as Orserdu, is an estrogen receptor antagonist used to treat advanced or metastatic breast lesions. It is indicated for postmenopausal women or adult men, especially those who ...
Elacestrant detailed instructions, precautions, efficacy, dosage introduction
Elacestrant, is an estrogen receptor antagonist used to treat ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast lesions. It blocks the growth and spread of diseased cells by inhib...
Dosage and Administration of Elacestrant(Orserdu)
Elacestrant(Orserdu) is a novel estrogen receptor antagonist designed for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations. It inhibits the growth...
Related Articles
Side Effects of Binimetinib (Mektovi)
Binimetinib (Mektovi) is a selective mitogen-activated protein kinase (MEK) inhibitor. It primarily blocks the RAS/RAF/MEK/ERK signaling pathway by inhibiting the activity of MEK1 and MEK2, thereby su...
What Are the Precautions for Binimetinib (Mektovi) Use?
Binimetinib (Mektovi) is a MEK inhibitor, usually used in combination with encorafenib, for the treatment of unresectable or metastatic melanoma positive for BRAF V600E or V600K mutations, as well as ...
Dosage and Administration, Recommended Dose of Binimetinib (Mektovi)
Binimetinib (Mektovi) is a kinase inhibitor, usually used in combination with encorafenib, for the treatment of unresectable or metastatic melanoma positive for BRAF V600E or V600K mutations, as well ...
What Are the Purchase Channels for Binimetinib (Mektovi)?
Binimetinib (Mektovi) is an important MEK inhibitor that plays a key role in the treatment of melanoma and lung cancer. As this medication is a prescription drug and related to significant health and ...
What are the Indications of Binimetinib (Mektovi)?
Binimetinib (Mektovi) is a highly potent and selective mitogen-activated protein kinase (MEK) inhibitor that plays a crucial role in the field of cancer treatment. As a molecular targeted therapy drug...
Can pregnant and lactating women use Binimetinib?
Binimetinib, also known as Mektovi, is a drug used to treat certain types of diseases, particularly melanotic lesions associated with specific gene mutations. It belongs to a class of drugs called MEK...
Precautions for Binimetinib use
Binimetinib is a targeted therapy drug that is primarily used to treat certain types of diseases, especially those associated with BRAF gene mutations.Basic information about BinimetinibBinimetinib is...
Precautions for the use of Binimetinib(Mektovi)
Binimetinib is a targeted drug used to treat specific types of lesions. This article will introduce the precautions for the use of Binimetinib to help patients better understand how to use the drug sa...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved